[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"myelopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:myelopathy":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100455971","phase-1-combining-low-oxygen-therapy-and-an-adenosine-a2a-receptor-antagonist-to-improve-functional-mobility-after-spinal-cord-injury-100455971",false,"NCT05217498","Combining Low Oxygen Therapy and an Adenosine A2a Receptor Antagonist to Improve Functional Mobility After Spinal Cord Injury","A Selective Adenosine 2a Antagonist to Enhance Training-related Gains in Walking Function for Persons With Chronic, Incomplete Spinal Cord Injury","Inclusion Criteria:\n\n1. age 18 and 75 years (the latter to reduce the likelihood of heart disease) medical clearance to participate\n2. lesion at or below C2 and above T12 with non-progressive etiology\n3. classified as motor-incomplete with visible volitional leg movement\n4. injury greater than 12 months\n5. ability to advance one step overground without human assistance\n\nExclusion Criteria:\n\n1. Concurrent severe medical illness (i.e., infection, cardiovascular disease, ossification, recurrent autonomic dysreflexia, unhealed decubiti, and history of pulmonary complications)\n2. Pregnant women because of the unknown effects of AIH on pregnant women and fetus\n3. History of seizures, brain injury, and\u002For epilepsy\n4. Undergoing concurrent physical therapy\n5. Diabetes\n6. Cirrhosis Caffeine and\u002For NSAID allergies or intolerances","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.",[28,29],"Spinal Cord Injuries","Myelopathy",[31,32,33,34,35,36],"spinal cord injury","walking","motor control","istradefylline","adenosine","strength","NOT_YET_RECRUITING","2026-03-18",{"date":40,"type":41},"2026-03-20","ACTUAL",{"date":43,"type":21},"2027-09-01",{"date":45,"type":21},"2028-06-30",{"name":47,"class":48},"Randy Trumbower, PT, PhD","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":49},"100551796","efficacy-of-rtms-treatment-after-spinal-cord-injury-100551796","NCT06464744","Efficacy of rTMS Treatment After Spinal Cord Injury","Investigating the Efficacy of rTMS Treatment in Improving Motor Function After Spinal Cord Injury: A Placebo-controlled Study","Inclusion Criteria:\n\n* Age over 18 years and less than 80 years\n* Chronic patients with an incomplete cervical and\u002For thoracic spinal cord injury (traumatic and non-traumatic) affecting upper and\u002For lower extremities (i.e., C4-T12 and classified as ASIA C or D) (Figure 138).\n* Capable and willing to provide informed consent and able to adhere to the treatment schedule\n* Patients who can be followed for the whole duration of the study\n\n6.3 Exclusion criteria\n\n* Contraindication to rTMS:\n\n  * past severe head trauma\n  * history of epilepsy or ongoing epilepsy\n  * active cerebral tumor\n  * intracranial hypertension\n  * implanted ferromagnetic devices such as cardiac pacemaker and neurostimulator and cochlear implants\n  * pregnancy or lactation.\n* Any clinically significant or unstable medical or psychiatric disorder\n* Other ongoing research protocol or recent past protocol within two months before the inclusion\n* History of treatment with Deep Brain Stimulation (DBS)\n* Subjects protected by law (guardianship or tutelage measure)\n* History of substance abuse (alcohol, drugs)\n* Pending litigation\n* Impossibility to understand the protocol or to fill out the forms\n* Chronic use of sedative medication\n* Participation in another clinical trial evaluating spinal cord injury",true,"80 Years",{"count":60,"type":21},20,[62],"NA","There is accumulating evidence that neuromodulation by repetitive transcranial magnetic stimulation (rTMS) of the motor cortex holds promise as a treatment for rehabilitation of motor function following a spinal cord injury. This study is designed to assess the clinical potential of non-invasive stimulation of the primary motor cortex to improve motor functions.The results will help to evaluate the clinical relevance of motor cortex stimulation for motor functions in patients with spinal cord injury. The outcomes of this study could potentially support the initiation of a larger clinical trial and the development of a new routine treatment.",[28,29],[66,67,31,68],"rTMS","rehabilitation","motor cortex stimulation","RECRUITING","2024-06-17",{"date":72,"type":41},"2024-06-18",{"date":74,"type":41},"2024-01-15",{"date":76,"type":21},"2029-09",{"name":78,"class":48},"Oslo University Hospital",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":58,"enrollmentInfo":87,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":49},"100410973","phase-3-regeneration-in-cervical-degenerative-myelopathy-100410973","NCT04631471","Regeneration in Cervical Degenerative Myelopathy","Regeneration in Cervical Degenerative Myelopathy - a Multi-centre, Double-blind, Randomised, Placebo Controlled Trial Assessing the Efficacy of Ibudilast as an Adjuvant Treatment to Decompressive Surgery for Degenerative Cervical Myelopathy","RECEDE","Inclusion Criteria:\n\n* Patients suffering from degenerative cervical myelopathy as per established criteria who have granted informed consent to participate in the trial\n* Have a preoperative mJOA score ≥8 and ≤14\n* Scheduled for first surgical decompression as part of usual NHS clinical practice\n\nExclusion Criteria:\n\n* Previous surgery for DCM\n* DCM symptoms due to cervical trauma (at the discretion of the investigator)\n* Hypersensitivity to Ibudilast or any of the formulation components\n* Evidence of acute hepatitis, clinically significant chronic hepatitis, or evidence of clinically significant impaired hepatic function through clinical and laboratory evaluation including ALP\\> 1.5x ULN; ALT or AST \\> 2x ULN; GGT \\> 3x ULN\n* Active malignancy defined as history of invasive malignancy, except if the patient has received treatment and displayed no clinical signs and symptoms for at least five years\n* Recent history (less than 3 years) of chemical substance dependency or significant psychosocial disturbance that may impact the outcome or study participation\n* Female patients with child bearing potential who are unwilling or unable to use reliable methods of contraception\n* Female patients who are pregnant, lactating or planning pregnancy during the course of the trial\n* Inability to comply with study procedures, IMP regime or follow-up schedule\n* Unable to take a gelatin based product\n* Participation in another CTIMP or device within the past 30 days from the time of recruitment\n* Functional disability from a commitment neurological disease that would mask the symptoms of DCM (at the discretion of the investigator). Including but not limited to stroke with residual disability, cerebellar ataxia, Parkinson's disease, symptomatic lumbar stenosis and multiple sclerosis\n* Resting pulse \\\u003C 50 bpm, SA or AV block, uncontrolled hypertension, or QTcF \\> 450 ms\n* History of stomach or intestinal surgery or any other condition that could interfere with or is judged by the Investigator to interfere with absorption, distribution, metabolism, or excretion of study drug\n* Unable to converse, read or write English at primary school level",{"count":88,"type":21},400,[90],"PHASE3","Degenerative (wear and tear arthritis of the spine) Cervical (concerning the neck) Myelopathy (injury to the spinal cord), DCM, is the most common spinal cord disorder of adulthood. In DCM, arthritis of the spine causes compression of the spinal cord.\n\nThe symptoms of DCM are often mistaken for natural consequences of ageing, including numb and clumsy hands, loss of coordination, imbalance, bladder and bowel problems. The weakness can progress to severe paralysis. Every year approximately 4 individuals in 100,000 undergo surgery for DCM; however, many more individuals are thought to suffer from DCM.\n\nThe main treatment for DCM is surgery. The aim of surgery is to create space and remove the compression of the spinal cord. This is known to prevent further injury. Unfortunately, the post-operative improvements are often incomplete and many patients remain severely disabled. Improving outcome after surgery represents an important unmet clinical need.\n\nClinical and preclinical findings indicate that the drug Ibudilast can stimulate neuroprotective and regenerative processes in the spinal cord. Ibudilast is well-tolerated and used to treat asthma and post-stroke dizziness in Japan and is currently being investigated for use in treating other neurological diseases.\n\nThis study will investigate whether daily oral administration of Ibudilast for a maximum of 34 weeks can improve hand function, strength, balance, urinary problems and reduce pain.\n\nThe study will initially be conducted at three sites in the UK, with more sites added as necessary. Individuals between 18-80 years old, diagnosed with DCM and scheduled for an operation for the first time will be invited to participate in the trial. The study will entail patient questionnaires and clinical assessments before surgery, shortly after surgery and 3, 6, and 12 months after surgery. Moreover, patients will undergo MRI scans pre-operatively and at 6-months postoperatively to determine whether the treatment was successful.",[29,93],"Spinal Cord Diseases",[95,96,29],"Degenerative","Cervical","2021-12-24",{"date":99,"type":41},"2022-01-13",{"date":101,"type":41},"2021-12-22",{"date":103,"type":21},"2026-09-01",{"name":105,"class":48},"Cambridge University Hospitals NHS Foundation Trust"]